Impact of tofacitinib treatment on human B-cells in vitro and in vivo

Journal of Autoimmunity

Volumn 77, Issue , 2017, Pages 55-66

  Rizzi, Marta ^a   Lorenzetti, Raquel ^a   Fischer, Kathleen ^a   Staniek, Julian ^a   Janowska, Iga ^a   Troilo, Arianna ^a   Strohmeier, Valentina ^a   Erlacher, Miriam ^a   Kunze, Mirjam ^a   Bannert, Bettina ^a,b   Kyburz, Diego ^b   Voll, Reinhard E ^a   Venhoff, Nils ^a   Thiel, Jens ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

B lymphocytes; Immune modulation; JAK inhibitors; Rheumatoid arthritis; Tofacitinib; tsDMARDs

Indexed keywords

ANTIGEN; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; IMMUNOGLOBULIN; TOFACITINIB; X BOX BINDING PROTEIN 1; AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; INTERLEUKIN 2 RECEPTOR GAMMA; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL FATE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; PLASMABLAST; POLYARTHRITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTIBODY PRODUCTION; B LYMPHOCYTE; CELL CULTURE; DRUG EFFECTS; GENE REARRANGEMENT; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; PLASMA CELL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CELLS, CULTURED; CYTIDINE DEAMINASE; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOMODULATION; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; PIPERIDINES; PLASMA CELLS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION;

EID: 84992690570     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.10.005     Document Type: Article

References (52)

1. [1] Smolen, J.S., Aletaha, D., McInnes, I.B., Rheumatoid arthritis. Lancet, 2016 Epub ahead of print.
2. [2] O'Shea, J.J., Plenge, R., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36 (2012), 542–550.
3. [3] Walker, J.G., Ahern, M.J., Coleman, M., Weedon, H., Papangelis, V., Beroukas, D., et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann. Rheumatic Dis. 65 (2006), 1558–1564.
4. [4] Ghoreschi, K., Laurence, A., O'Shea, J.J., Janus kinases in immune cell signaling. Immunol. Rev. 228 (2009), 273–287.
5. [5] Ghoreschi, K., Jesson, M.I., Li, X., Lee, J.L., Ghosh, S., Alsup, J.W., et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186 (2011), 4234–4243.
6. [6] Riese, R.J., Krishnaswami, S., Kremer, J., Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract. Res. Clin. Rheumatology 24 (2010), 513–526.
7. [7] Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460.
8. [8] Cutolo, M., The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential. Ther. Adv. Musculoskelet. Dis. 5 (2013), 3–11.
9. [9] Cutolo, M., Meroni, M., Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis. J. Inflamm. Res. 6 (2013), 129–137.
10. [10] van Vollenhoven, R.F., Fleischmann, R., Cohen, S., Lee, E.B., Garcia Meijide, J.A., Wagner, S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367 (2012), 508–519.
11. [11] van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheumatism 65 (2013), 559–570.
12. [12] Casanova, J.L., Holland, S.M., Notarangelo, L.D., Inborn errors of human JAKs and STATs. Immunity 36 (2012), 515–528.
13. [13] Dechanet, J., Merville, P., Durand, I., Banchereau, J., Miossec, P., The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. J. Clin. Investigation 95 (1995), 456–463.
14. [14] Schroder, A.E., Greiner, A., Seyfert, C., Berek, C., Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 221–225.
15. [15] Nakken, B., Munthe, L.A., Konttinen, Y.T., Sandberg, A.K., Szekanecz, Z., Alex, P., et al. B-cells and their targeting in rheumatoid arthritis–current concepts and future perspectives. Autoimmun. Rev. 11 (2011), 28–34.
16. [16] Avery, D.T., Deenick, E.K., Ma, C.S., Suryani, S., Simpson, N., Chew, G.Y., et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207 (2010), 155–171.
17. [17] Leonard, W.J., Role of Jak kinases and STATs in cytokine signal transduction. Int. J. Hematol. 73 (2001), 271–277.
18. [18] Recher, M., Berglund, L.J., Avery, D.T., Cowan, M.J., Gennery, A.R., Smart, J., et al. IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood 118 (2011), 6824–6835.
19. [19] Macchi, P., Villa, A., Giliani, S., Sacco, M.G., Frattini, A., Porta, F., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377 (1995), 65–68.
20. [20] Wjst, M., Lichtner, P., Meitinger, T., Grimbacher, B., STAT3 single-nucleotide polymorphisms and STAT3 mutations associated with hyper-IgE syndrome are not responsible for increased serum IgE serum levels in asthma families. Eur. J. Hum. Genet. EJHG 17 (2009), 352–356.
21. [21] Kienzler, A.K., Rizzi, M., Reith, M., Nutt, S.L., Eibel, H., Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid. J. allergy Clin. Immunol. 131 (2013), 1695–1699.
22. [22] Warnatz, K., Salzer, U., Rizzi, M., Fischer, B., Gutenberger, S., Bohm, J., et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 13945–13950.
23. [23] Palanichamy, A., Barnard, J., Zheng, B., Owen, T., Quach, T., Wei, C., et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 182 (2009), 5982–5993.
24. [24] Muller, P.Y., Janovjak, H., Miserez, A.R., Dobbie, Z., Processing of gene expression data generated by quantitative real-time RT-PCR. BioTechniques 32 (2002), 1372–1374 6, 8-9.
25. [25] Tangye, S.G., Ma, C.S., Brink, R., Deenick, E.K., The good, the bad and the ugly - TFH cells in human health and disease. Nat. Rev. Immunol. 13 (2013), 412–426.
26. [26] Tellier, J., Shi, W., Minnich, M., Liao, Y., Crawford, S., Smyth, G.K., et al. Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat. Immunol. 17 (2016), 323–330.
27. [27] Klein, U., Casola, S., Cattoretti, G., Shen, Q., Lia, M., Mo, T., et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat. Immunol. 7 (2006), 773–782.
28. [28] Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., Honjo, T., Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 (2000), 553–563.
29. [29] Revy, P., Muto, T., Levy, Y., Geissmann, F., Plebani, A., Sanal, O., et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102 (2000), 565–575.
30. [30] Jiang, J.K., Ghoreschi, K., Deflorian, F., Chen, Z., Perreira, M., Pesu, M., et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-y l)-3-oxopropanenitrile (CP-690,550). J. Med. Chem. 51 (2008), 8012–8018.
31. [31] Flanagan, M.E., Blumenkopf, T.A., Brissette, W.H., Brown, M.F., Casavant, J.M., Shang-Poa, C., et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 53 (2010), 8468–8484.
32. [32] Dowty, M.E., Jesson, M.I., Ghosh, S., Lee, J., Meyer, D.M., Krishnaswami, S., et al. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 348 (2014), 165–173.
33. [33] Herzog, S., Reth, M., Jumaa, H., Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat. Rev. Immunol. 9 (2009), 195–205.
34. [34] Onda, M., Ghoreschi, K., Steward-Tharp, S., Thomas, C., O'Shea, J.J., Pastan, I.H., et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J. Immunol. 193 (2014), 48–55.
35. [35] Calame, K.L., Lin, K.I., Tunyaplin, C., Regulatory mechanisms that determine the development and function of plasma cells. Annu. Rev. Immunol. 21 (2003), 205–230.
36. [36] Ettinger, R., Sims, G.P., Fairhurst, A.M., Robbins, R., da Silva, Y.S., Spolski, R., et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175 (2005), 7867–7879.
37. [37] Wang, S.P., Iwata, S., Nakayamada, S., Sakata, K., Yamaoka, K., Tanaka, Y., Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann. Rheumatic Dis. 73 (2014), 2213–2215.
38. [38] Kracker, S., Durandy, A., Insights into the B cell specific process of immunoglobulin class switch recombination. Immunol. Lett. 138 (2011), 97–103.
39. [39] Salzer, E., Kansu, A., Sic, H., Majek, P., Ikinciogullari, A., Dogu, F.E., et al. Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J. allergy Clin. Immunol. 133 (2014), 1651–1659 e12.
40. [40] Kotlarz, D., Zietara, N., Uzel, G., Weidemann, T., Braun, C.J., Diestelhorst, J., et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J. Exp. Med. 210 (2013), 433–443.
41. [41] Deenick, E.K., Avery, D.T., Chan, A., Berglund, L.J., Ives, M.L., Moens, L., et al. Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J. Exp. Med. 210 (2013), 2739–2753.
42. [42] Giesecke, C., Frolich, D., Reiter, K., Mei, H.E., Wirries, I., Kuhly, R., et al. Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells. J. Immunol. 192 (2014), 3091–3100.
43. [43] Good, K.L., Avery, D.T., Tangye, S.G., Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J. Immunol. 182 (2009), 890–901.
44. [44] Bernasconi, N.L., Traggiai, E., Lanzavecchia, A., Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 (2002), 2199–2202.
45. [45] Tangye, S.G., Avery, D.T., Deenick, E.K., Hodgkin, P.D., Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J. Immunol. 170 (2003), 686–694.
46. [46] van Gurp, E.A., Schoordijk-Verschoor, W., Klepper, M., Korevaar, S.S., Chan, G., Weimar, W., et al. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 87 (2009), 79–86.
47. [47] Strober, B., Buonanno, M., Clark, J.D., Kawabata, T., Tan, H., Wolk, R., et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br. J. Dermatology 169 (2013), 992–999.
48. [48] Noguchi, M., Yi, H., Rosenblatt, H.M., Filipovich, A.H., Adelstein, S., Modi, W.S., et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73 (1993), 147–157.
49. [49] Puck, J.M., Deschenes, S.M., Porter, J.C., Dutra, A.S., Brown, C.J., Willard, H.F., et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum. Mol. Genet. 2 (1993), 1099–1104.
50. [50] Kraus, H., Kaiser, S., Aumann, K., Bonelt, P., Salzer, U., Vestweber, D., et al. A feeder-free differentiation system identifies autonomously proliferating B cell precursors in human bone marrow. J. Immunol. 192 (2014), 1044–1054.
51. [51] Parrish, Y.K., Baez, I., Milford, T.A., Benitez, A., Galloway, N., Rogerio, J.W., et al. IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J. Immunol. 182 (2009), 4255–4266.
52. [52] Piscianz, E., Valencic, E., Cuzzoni, E., De Iudicibus, S., De Lorenzo, E., Decorti, G., et al. Fate of lymphocytes after withdrawal of tofacitinib treatment. PloS One, 9, 2014, e85463.